Recent corporate updates for Atea Pharmaceuticals (NASDAQ: AVIR) focus on clinical trial updates for its oral antiviral pipeline targeting severe viral diseases such as hepatitis C and respiratory syncytial virus (RSV), alongside ongoing cash runway management.